

# Clifford J Bailey

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5745157/clifford-j-bailey-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

10,220  
citations

37  
h-index

101  
g-index

105  
ext. papers

12,469  
ext. citations

10.5  
avg, IF

6.91  
L-index

#	Paper	IF	Citations
92	Metformin. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 574-9	59.2	1610
91	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , <b>2020</b> , 41, 255-323	9.5	1360
90	Oral antidiabetic agents: current role in type 2 diabetes mellitus. <i>Drugs</i> , <b>2005</b> , 65, 385-411	12.1	828
89	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2010</b> , 375, 2223-33	40	644
88	Biguanides and NIDDM. <i>Diabetes Care</i> , <b>1992</b> , 15, 755-72	14.6	498
87	Management of type 2 diabetes: new and future developments in treatment. <i>Lancet, The</i> , <b>2011</b> , 378, 182-97	40	398
86	Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2668-75	27.4	355
85	Metformin and the gastrointestinal tract. <i>Diabetologia</i> , <b>2016</b> , 59, 426-35	10.3	330
84	Use of metformin in the setting of mild-to-moderate renal insufficiency. <i>Diabetes Care</i> , <b>2011</b> , 34, 1431-7	14.6	304
83	Type 2 diabetes in adolescents and young adults. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2018</b> , 6, 69-80	18.1	273
82	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 129-139	59.2	243
81	SGLT inhibitors in management of diabetes. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2013</b> , 1, 140-51	18.1	215
80	Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. <i>BMC Medicine</i> , <b>2013</b> , 11, 43	11.4	206
79	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2016</b> , 12, 566-92	15.2	205
78	The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. <i>Drugs</i> , <b>1999</b> , 58 Suppl 1, 31-9; discussion 75-82	12.1	187
77	Renal glucose reabsorption inhibitors to treat diabetes. <i>Trends in Pharmacological Sciences</i> , <b>2011</b> , 32, 63-71	13.2	156
76	Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. <i>Diabetes</i> , <b>2005</b> , 54, 2436-46	0.9	140

75	Insulin-like effect of pinitol. <i>British Journal of Pharmacology</i> , <b>2000</b> , 130, 1944-8	8.6	137
74	A risk-benefit assessment of metformin in type 2 diabetes mellitus. <i>Drug Safety</i> , <b>1999</b> , 20, 489-503	5.1	133
73	Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. <i>Biochemical Pharmacology</i> , <b>1988</b> , 37, 4353-8	6	98
72	Insulin therapy in people with type 2 diabetes: opportunities and challenges?. <i>Diabetes Care</i> , <b>2014</b> , 37, 1499-508	14.6	94
71	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 620-628	6.7	89
70	Metformin: effects on micro and macrovascular complications in type 2 diabetes. <i>Cardiovascular Drugs and Therapy</i> , <b>2008</b> , 22, 215-24	3.9	83
69	New drugs for type 2 diabetes mellitus: what is their place in therapy?. <i>Drugs</i> , <b>2008</b> , 68, 2131-62	12.1	82
68	Uric acid and the cardio-renal effects of SGLT2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1291-1298	6.7	68
67	Future glucose-lowering drugs for type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 350-9	18.1	67
66	Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1548-61	3.5	62
65	Potential new treatments for type 2 diabetes. <i>Trends in Pharmacological Sciences</i> , <b>2000</b> , 21, 259-65	13.2	61
64	Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. <i>Frontiers in Bioscience - Landmark</i> , <b>2008</b> , 13, 3648-60	2.8	60
63	Insulin resistance and antidiabetic drugs. <i>Biochemical Pharmacology</i> , <b>1999</b> , 58, 1511-20	6	51
62	Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. <i>American Journal of Medicine</i> , <b>2010</b> , 123, 374.e 9 -18	2.4	45
61	Age-associated changes in long-chain fatty acid profile during healthy aging promote pro-inflammatory monocyte polarization via PPAR $\alpha$ . <i>Aging Cell</i> , <b>2016</b> , 15, 128-39	9.9	45
60	Drugs on the horizon for diabetes. <i>Current Diabetes Reports</i> , <b>2005</b> , 5, 353-9	5.6	43
59	GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. <i>Journal of Medicinal Chemistry</i> , <b>2006</b> , 49, 1047-54	8.3	40
58	The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios. <i>Journal of Clinical and Translational Endocrinology</i> , <b>2017</b> , 7, 21-27	2.4	37

57	Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. <i>Biochemical Pharmacology</i> , <b>2009</b> , 78, 1008-16	6	37
56	Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. <i>Biochemical Journal</i> , <b>2002</b> , 367, 913-20	3.8	32
55	The therapeutic use of lipoic acid in diabetes: a current perspective. <i>Environmental Toxicology and Pharmacology</i> , <b>2001</b> , 10, 167-72	5.8	32
54	Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 147	8.7	31
53	Why is Exubera being withdrawn? <b>2007</b> , 335, 1156-1156		31
52	Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2013</b> , 10, 397-409	3.3	30
51	Treating insulin resistance: future prospects. <i>Diabetes and Vascular Disease Research</i> , <b>2007</b> , 4, 20-31	3.3	30
50	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 3-14	6.7	29
49	Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. <i>International Journal of Clinical Practice</i> , <b>2016</b> , 70, 988-995	2.9	25
48	Interpreting adverse signals in diabetes drug development programs. <i>Diabetes Care</i> , <b>2013</b> , 36, 2098-106	14.6	20
47	Human islet isolation: semi-automated and manual methods. <i>Diabetes and Vascular Disease Research</i> , <b>2007</b> , 4, 7-12	3.3	20
46	Type 2 diabetes mellitus in older adults: clinical considerations and management. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 534-548	15.2	20
45	The challenge of managing coexistent type 2 diabetes and obesity. <i>BMJ, The</i> , <b>2011</b> , 342, d1996	5.9	19
44	GIP analogues and the treatment of obesity-diabetes. <i>Peptides</i> , <b>2020</b> , 125, 170202	3.8	19
43	The future of new drugs for diabetes management. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 155, 107785	7.4	18
42	Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. <i>Diabetes Care</i> , <b>2020</b> , 43, 244-246	14.6	16
41	Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides. <i>Peptides</i> , <b>2018</b> , 100, 9-17	3.8	14
40	What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. <i>Diabetes and Vascular Disease Research</i> , <b>2009</b> , 6, 283-7	3.3	12

39	Low gravity rotational culture and the integration of immunomodulatory stem cells reduce human islet allo-reactivity. <i>Clinical Transplantation</i> , <b>2015</b> , 29, 90-8	3.8	11
38	Treatment of type 2 diabetes: future approaches. <i>British Medical Bulletin</i> , <b>2018</b> , 126, 123-137	5.4	11
37	Diabetes therapies in renal impairment. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2012</b> , 12, 167-171		11
36	New pharmacologic agents for diabetes. <i>Current Diabetes Reports</i> , <b>2001</b> , 1, 119-26	5.6	11
35	Rotational culture and integration with amniotic stem cells reduce porcine islet immunoreactivity in vitro and slow xeno-rejection in a murine model of islet transplantation. <i>Xenotransplantation</i> , <b>2019</b> , 26, e12508	2.8	9
34	Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 1017-25	5.9	9
33	New therapies for diabetes. <i>Current Diabetes Reports</i> , <b>2009</b> , 9, 360-7	5.6	9
32	Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2564-2569	6.7	7
31	Could FFAR1 assist insulin secretion in type 2 diabetes?. <i>Lancet, The</i> , <b>2012</b> , 379, 1370-1	4.0	7
30	Phenotypic characteristics and risk factors in a multi-ethnic cohort of young adults with type 2 diabetes. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1893-1900	2.5	6
29	Inhaled insulin: new formulation, new trial. <i>Lancet, The</i> , <b>2010</b> , 375, 2199-201	4.0	6
28	Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 784459	5.6	6
27	The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. <i>Diabetes and Vascular Disease Research</i> , <b>2006</b> , 3, 186-8	3.3	5
26	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.. <i>Current Diabetes Reports</i> , <b>2022</b> , 22, 39	5.6	5
25	Flash Continuous Glucose Monitoring: A Summary Review of Recent Real-World Evidence. <i>Clinical Diabetes</i> , <b>2021</b> , 39, 64-71	2.9	4
24	Future Drug Treatments for Type 2 Diabetes1017-1044		4
23	Insulin resistance: Impact on therapeutic developments in diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2019</b> , 16, 128-132	3.3	3
22	Review: Pharmacological approaches to reduce adiposity. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2006</b> , 6, 121-125		3

21	Functional enhancement of electrofusion-derived BRIN-BD11 insulin-secreting cells after implantation into diabetic mice. <i>International Journal of Experimental Diabetes Research</i> , <b>2001</b> , 2, 29-36		3
20	Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 130, 155160	12.7	3
19	Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2020</b> , 8, 97-99	18.1	3
18	Tirzepatide: a new low for bodyweight and blood glucose. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2021</b> , 9, 646-648	18.1	3
17	Treating T2DM and obesity with bariatric surgery and GLP1 agents. <i>Nature Reviews Endocrinology</i> , <b>2019</b> , 15, 504-506	15.2	2
16	Oral Antidiabetic Agents <b>2010</b> , 452-477		2
15	Metformin in women with type 2 diabetes in pregnancy. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2020</b> , 8, 802-803	18.1	2
14	Treatment with Metformin <b>2013</b> , 99-116		1
13	Future Drug Treatments for Type 2 Diabetes <b>2016</b> , 1000-1011		1
12	Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen. <i>Diabetes Technology and Therapeutics</i> , <b>2021</b> , 23, S19-S27	8.1	1
11	New Drugs for the Treatment of Diabetes Mellitus		1
10	Odd chain fatty acid metabolism in mice after a high fat diet.. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2021</b> , 143, 106135	5.6	0
9	The potential role of multifunctional human amniotic epithelial cells in pancreatic islet transplantation. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , <b>2021</b> , 15, 599-611	4.4	0
8	New drugs for the treatment of diabetes mellitus <b>2015</b> , 709-725		
7	Overview of new and developing pharmacological treatments. <i>Country Review Ukraine</i> , <b>2005</b> , 7, D23-D26		
6	Future therapies. <i>Current Medical Research and Opinion</i> , <b>2002</b> , 18 Suppl 1, s82-8	2.5	
5	Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. <i>Diabetes Care</i> 2020;43:244-246. <i>Diabetes Care</i> , <b>2020</b> , 43, e159	14.6	
4	Glucose-Lowering Drugs Other than Insulin <b>2020</b> , 1-17		

3 Oral Glucose-Lowering Agents **2016**, 426-454

2 FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1079-1080 6.7

1 European Medicines Agency: Approval of new glucose-lowering medicines for type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2057-2058 6.7